12 January - 20 June 2016

Researchers study Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome

21 October 2015

A recent study into the use of probiotics in the treatment of irritable bowel syndrome (IBS) has shown that Saccharomyces cerevisiae CNCM I-3856 may improve gastrointestinal symptoms in patients suffering from IBS-C (constipation predominant IBS).

Probiotics have been an area of interest in the treatment of this highly prevalent disorder due to the perceived low likelihood of unwanted systemic effects. In this randomized double blind placebo-controlled trial, a total of 379 subjects who had been diagnosed with IBS were split into two groups, a placebo and active group. The active group took S. cerevisiae I-3856 (1000 mg, 8 x 109 colony forming units (CFU)/g) and the placebo group took calcium phosphate and maltodextrin, daily, for 12 weeks. Within the active group, 42.7% were diagnosed as suffering with IBS-C.

While no improvements in overall wellbeing of all patients within the active group was documented, a significant reduction in abdominal pain and bloating was recorded in patients with IBS-C. The underlying mechanism of this effect is unclear however it has been hypothesized that it could be related to accelerated bowel transit.

share this article
RSSL endeavours to check the veracity of news stories cited in this free e-mail bulletin by referring to the primary source, but cannot be held responsible for inaccuracies in the articles so published. RSSL provides links to other World Wide Web sites as a convenience to users, but cannot be held responsible for the content or availability of these sites. This document may be copied and distributed provided the source is cited as RSSL's Food e-News and the information so distributed is not used for profit.

Previous editions

Load more editions

Make an Enquiry